

Section: [6. Anti-infective medicines](#) > [6.4. Antiviral medicines](#) > [6.4.2. Antiretrovirals](#) > [6.4.2.3. Antiretrovirals > Protease inhibitors](#)

		EMLc	ATC codes: <a href="#">J05AE01</a>
Indication	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified	ICD11 code: <a href="#">1C62.Z</a>	
INN	Saquinavir		
Medicine type	Chemical agent		
List type	Core (EML) (EMLc)		
Formulations	Oral > Solid: 200 mg ; 500 mg		
EML status history	First added in 2002 ( <a href="#">TRS 914</a> ) Changed in 2007 ( <a href="#">TRS 950</a> ) Changed in 2009 ( <a href="#">TRS 958</a> ) Removed in 2017 ( <a href="#">TRS 1006</a> )		
Sex	All		
Age	Also recommended for children		
Weight restriction	> 25 kg		
Therapeutic alternatives	The recommendation is for this specific medicine		
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . <a href="#">↗</a>		
Wikipedia	<a href="#">Saquinavir</a> <a href="#">↗</a>		
DrugBank	<a href="#">Saquinavir</a> <a href="#">↗</a>		

## Summary of evidence and Expert Committee recommendations

The Expert Committee recommended the deletion of saquinavir from the Model Lists, noting that that clinical use of the protease inhibitor saquinavir has declined over time with the introduction of newer antiretroviral agents with lower pill burden, similar or greater effectiveness and lower risk of toxicity. Unlike other protease inhibitors, saquinavir is associated with QT prolongation and a requirement for ECG monitoring. Numerous alternative protease inhibitors (with and without ritonavir) remain listed on the EML.

